phenol has been researched along with Growth Disorders in 1 studies
Growth Disorders: Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Linear models provided a simple and reliable tool to aid optimal monitoring of IGF-I by predicting mean and peak IGF-I levels based on an IGF-I sample following dosing of somapacitan." | 1.62 | Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan. ( Agersø, H; Højby Rasmussen, M; Juul Kildemoes, R; Overgaard, RV, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Juul Kildemoes, R | 1 |
| Højby Rasmussen, M | 1 |
| Agersø, H | 1 |
| Overgaard, RV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Open-labelled, Active-controlled, Multinational, Dose-escalation Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (NNC0195-0092, Somapacitan) Compared to Daily Dos[NCT01973244] | Phase 1 | 32 participants (Actual) | Interventional | 2013-12-16 | Completed | ||
| First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects[NCT01514500] | Phase 1 | 105 participants (Actual) | Interventional | 2012-01-16 | Completed | ||
| A Randomised, Open-labelled, Active-controlled, Multiple Dose, Dose Escalating, Sequential Dose Group Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once-weekly Long-acting Growth Hormone (NNC0195-0092, Somapacitan) Com[NCT01706783] | Phase 1 | 35 participants (Actual) | Interventional | 2012-10-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for phenol and Growth Disorders
| Article | Year |
|---|---|
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
Topics: Adult; Child; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Drug Monitoring; Foll | 2021 |
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
Topics: Adult; Child; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Drug Monitoring; Foll | 2021 |
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
Topics: Adult; Child; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Drug Monitoring; Foll | 2021 |
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
Topics: Adult; Child; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Drug Monitoring; Foll | 2021 |
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
Topics: Adult; Child; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Drug Monitoring; Foll | 2021 |
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
Topics: Adult; Child; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Drug Monitoring; Foll | 2021 |
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
Topics: Adult; Child; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Drug Monitoring; Foll | 2021 |
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
Topics: Adult; Child; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Drug Monitoring; Foll | 2021 |
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
Topics: Adult; Child; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Drug Monitoring; Foll | 2021 |